Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Dash Barry H | Director | ELITE PHARMACEUTICALS INCELTP | BuyP · Open-market or private purchase | 30,000 | $0.29 | $8,700 | 3,265,555Direct | Form 4 filed 10 Sep 2026, on sec.gov (opens in a new tab)Filed 10 Sep 2026 | |
| Plassche Douglas | EVP Operations | ELITE PHARMACEUTICALS INCELTP | OtherM · Option or derivative exercised or converted | 2,500,000 | $0.03 | $75,000 | 6,000,000Direct | Form 4 filed 13 Jan 2026, on sec.gov (opens in a new tab)Filed 13 Jan 2026 | |
| Plassche Douglas | EVP Operations | ELITE PHARMACEUTICALS INCELTP | SellS · Open-market or private sale | 800,000 | $0.62 | $496,000 | 3,500,000Direct | Form 4 filed 3 Oct 2025, on sec.gov (opens in a new tab)Filed 3 Oct 2025 | |
| ELITE PHARMACEUTICALS INC /NV/ | EVP Operations | ELITE PHARMACEUTICALS INCELTP | OtherM · Option or derivative exercised or converted | 2,500,000 | $0.03 | $75,000 | 4,300,000Direct | Form 4 filed 26 Aug 2025, on sec.gov (opens in a new tab)Filed 26 Aug 2025 | |
| ELITE PHARMACEUTICALS INC /NV/ | EVP Operations | ELITE PHARMACEUTICALS INCELTP | SellS · Open-market or private sale | 500,000 | $0.52 | $260,000 | 1,800,000Direct | Form 4 filed 26 Aug 2025, on sec.gov (opens in a new tab)Filed 26 Aug 2025 | |
| Kirkov Kirko | Chief Commercial Officer | ELITE PHARMACEUTICALS INCELTP | BuyP · Open-market or private purchase | 16,366 | $0.59 | $9,655.94 | 16,366Direct | Form 4 filed 25 Jul 2025, on sec.gov (opens in a new tab)Filed 25 Jul 2025 | |
| Plassche Douglas | EVP Operations | ELITE PHARMACEUTICALS INCELTP | SellS · Open-market or private sale | 200,000 | $0.58 | $116,000 | 2,300,000Direct | Form 4 filed 10 Jul 2025, on sec.gov (opens in a new tab)Filed 10 Jul 2025 | |
| Plassche Douglas | EVP Operations | ELITE PHARMACEUTICALS INCELTP | OtherM · Option or derivative exercised or converted | 2,500,000 | $0.03 | $75,000 | 2,500,000Direct | Form 4 filed 8 Jul 2025, on sec.gov (opens in a new tab)Filed 8 Jul 2025 | |
| Plassche Douglas | SVP of Operations | ELITE PHARMACEUTICALS INCELTP | SellS · Open-market or private sale | 333,932 | $0.51 | $170,305.32 | 0Direct | Form 4 filed 28 Oct 2024, on sec.gov (opens in a new tab)Filed 28 Oct 2024 | |
| Plassche Douglas | SVP of Operations | ELITE PHARMACEUTICALS INCELTP | SellS · Open-market or private sale | 800,000 | $0.49 | $392,000 | 333,932Direct | Form 4 filed 28 Oct 2024, on sec.gov (opens in a new tab)Filed 28 Oct 2024 | |
| Hakim Nasrat A | Director, CEO, President, 10% owner | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 49,534,368 | $0.00 | $0 | 216,649,250Direct | Form 4 filed 2 Apr 2024, on sec.gov (opens in a new tab)Filed 2 Apr 2024 | |
| Hakim Nasrat A | Director, CEO, President, 10% owner | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 2,223,147 | $0.07 | $155,620.29 | 2,223,147Indirect, Kristine Hakim | Form 4 filed 29 Dec 2023, on sec.gov (opens in a new tab)Filed 29 Dec 2023 | |
| Caskey Davis S | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 547,657 | $0.04 | $21,906.28 | 2,049,436Direct | Form 4 filed 27 Nov 2023, on sec.gov (opens in a new tab)Filed 27 Nov 2023 | |
| Dash Barry H | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 547,657 | $0.04 | $21,906.28 | 3,235,555Direct | Form 4 filed 27 Nov 2023, on sec.gov (opens in a new tab)Filed 27 Nov 2023 | |
| WHITNELL JEFFREY A | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 547,657 | $0.04 | $21,906.28 | 3,187,020Direct | Form 4 filed 27 Nov 2023, on sec.gov (opens in a new tab)Filed 27 Nov 2023 | |
| Dash Barry H | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 459,536 | $0.04 | $18,381.44 | 2,687,898Direct | Form 4 filed 29 Aug 2022, on sec.gov (opens in a new tab)Filed 29 Aug 2022 | |
| Caskey Davis S | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 459,536 | $0.04 | $18,381.44 | 1,501,779Direct | Form 4 filed 29 Aug 2022, on sec.gov (opens in a new tab)Filed 29 Aug 2022 | |
| WHITNELL JEFFREY A | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 459,536 | $0.04 | $18,381.44 | 2,639,363Direct | Form 4 filed 29 Aug 2022, on sec.gov (opens in a new tab)Filed 29 Aug 2022 | |
| Caskey Davis S | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 295,570 | $0.07 | $20,689.90 | 1,042,243Direct | Form 4 filed 1 Jul 2021, on sec.gov (opens in a new tab)Filed 1 Jul 2021 | |
| WHITNELL JEFFREY A | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 295,570 | $0.07 | $20,689.90 | 2,179,827Direct | Form 4 filed 1 Jul 2021, on sec.gov (opens in a new tab)Filed 1 Jul 2021 | |
| Dash Barry H | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 295,570 | $0.07 | $20,689.90 | 2,228,182Direct | Form 4 filed 1 Jul 2021, on sec.gov (opens in a new tab)Filed 1 Jul 2021 | |
| Hakim Nasrat A | Director, CEO & President, 10% owner | ELITE PHARMACEUTICALS INCELTP | OtherC · Conversion of a derivative security | 158,017,321 | $0.00 | $0 | 167,114,882Direct | Form 4 filed 26 Aug 2020, on sec.gov (opens in a new tab)Filed 26 Aug 2020 | |
| Dash Barry H | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 516,781 | $0.09 | $46,510.29 | 1,932,612Direct | Form 4 filed 24 Aug 2020, on sec.gov (opens in a new tab)Filed 24 Aug 2020 | |
| WHITNELL JEFFREY A | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 516,781 | $0.09 | $46,510.29 | 1,884,257Direct | Form 4 filed 24 Aug 2020, on sec.gov (opens in a new tab)Filed 24 Aug 2020 | |
| Caskey Davis S | Director | ELITE PHARMACEUTICALS INCELTP | OtherA · Grant or award from the company | 516,781 | $0.09 | $46,510.29 | 746,673Direct | Form 4 filed 24 Aug 2020, on sec.gov (opens in a new tab)Filed 24 Aug 2020 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.